KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Recursion Pharmaceuticals (RXRX) FCF Margin (2020 - 2025)

Recursion Pharmaceuticals (RXRX) has disclosed FCF Margin for 6 consecutive years, with 133.14% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, FCF Margin rose 243456.0% year-over-year to 133.14%, compared with a TTM value of 506.52% through Dec 2025, up 12719.0%, and an annual FY2025 reading of 506.52%, up 12719.0% over the prior year.
  • FCF Margin was 133.14% for Q4 2025 at Recursion Pharmaceuticals, up from 2272.52% in the prior quarter.
  • Across five years, FCF Margin topped out at 1369.7% in Q1 2022 and bottomed at 2590.68% in Q4 2021.
  • Average FCF Margin over 5 years is 923.79%, with a median of 698.95% recorded in 2023.
  • Peak annual rise in FCF Margin hit 2887673bps in 2021, while the deepest fall reached -269414bps in 2021.
  • Year by year, FCF Margin stood at 2590.68% in 2021, then soared by 95bps to 118.89% in 2022, then plummeted by -415bps to 611.77% in 2023, then plummeted by -320bps to 2567.71% in 2024, then surged by 95bps to 133.14% in 2025.
  • Business Quant data shows FCF Margin for RXRX at 133.14% in Q4 2025, 2272.52% in Q3 2025, and 413.92% in Q2 2025.